Investigational drug · Phase 2
PN-101
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Polymyositis, Dermatomyositis.
Phase 2Last checked: Nov 19, 2026Latest source record: Aug 14, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
2
Any phase or sponsor naming "PN-101"
First trial start
2025
Dec 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "PN-101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Polymyositis
- Dermatomyositis
Approved drugs for the same conditions: Dermatology
Largest trials
Live from ClinicalTrials.gov: studies naming "PN-101" as an intervention, largest first.
- Phase 2 Trial to Evaluate the Efficacy, Safety of Allogeneic Mitochondria (PN-101) in Patients With Refractory Polymyositis or DermatomyositisNot yet recruiting
Paean Biotechnology Inc.Industry
NCT07122648 · 36 participants (planned) · Start Dec 2025 · Primary completion Apr 2027
Drug: placebo; PN-101 and 1 more · For: Polymyositis; Dermatomyositis
Sites: Gwangmyeong, South Korea; Seoul, South Korea · 5 sites in all
- Allogeneic Mitochondria (PN-101) Transplantation for Refractory Polymyositis or DermatomyositisCompleted
Paean Biotechnology Inc.Industry
NCT04976140 · 9 participants · Start Dec 15, 2021 · Primary completion Oct 6, 2023
Drug: PN-101 · For: Polymyositis; Dermatomyositis
Sites: Seoul, South Korea · 3 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Therapeutic potential of mitochondrial transfer in reversing mutant-to-wild-type mtDNA ratio and improving mitochondrial dysfunction in 1555A>G mtDNA mutation-associated hearing loss.
Kim Y, Kim CH, Nam DW, et al. · Sci Rep 2026
- Mitochondrial transplantation restores mitochondrial content and function in SSBP1-related mitochondrial DNA depletion syndrome.
Kim D, Lee SE, Cha J, et al. · BMB Rep 2026
- Mitochondrial transplantation as a novel therapeutic approach in idiopathic inflammatory myopathy.
Kim JY, Kang YC, Kim MJ, et al. · Ann Rheum Dis 2025
- Mitochondrial Transplantation Ameliorates Pulmonary Fibrosis by Suppressing Myofibroblast Activation.
Lee SE, Yu SH, Kim IH, et al. · Int J Mol Sci 2024
- Mitochondrial transplantation exhibits neuroprotective effects and improves behavioral deficits in an animal model of Parkinson's disease.
Eo H, Yu SH, Choi Y, et al. · Neurotherapeutics 2024
- Erratum to: Human umbilical cord mesenchymal stem cell-derived mitochondria (PN-101) attenuate LPS-induced inflammatory responses by inhibiting NFκB signaling pathway.
Yu SH, Kim S, Kim Y, et al. · BMB Rep 2022
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.